Analysts Offer Predictions for Equillium FY2029 Earnings

Equillium, Inc. (NASDAQ:EQ) – Equities researchers at Leerink Partnrs issued their FY2029 EPS estimates for shares of Equillium in a research report issued to clients and investors on Friday, March 28th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of ($0.06) per share for the year. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Equillium’s current full-year earnings is $0.14 per share.

Equillium (NASDAQ:EQ) last posted its earnings results on Thursday, March 27th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.06. Equillium had a negative return on equity of 20.68% and a negative net margin of 10.05%. The company had revenue of $4.39 million for the quarter.

Separately, Leerink Partners restated a “market perform” rating and issued a $1.00 target price (down from $3.00) on shares of Equillium in a research note on Friday.

Equillium Stock Down 3.2 %

Shares of Equillium stock opened at $0.39 on Monday. The company has a market cap of $13.90 million, a P/E ratio of -2.80 and a beta of 1.87. The firm’s 50 day moving average price is $0.75 and its 200-day moving average price is $0.79. Equillium has a 52-week low of $0.36 and a 52-week high of $2.43.

Hedge Funds Weigh In On Equillium

An institutional investor recently raised its position in Equillium stock. DCF Advisers LLC raised its stake in shares of Equillium, Inc. (NASDAQ:EQ) by 91.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,947 shares of the company’s stock after purchasing an additional 29,985 shares during the quarter. DCF Advisers LLC owned about 0.18% of Equillium worth $47,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 27.05% of the company’s stock.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.